BioPharma Resources

Drugs by condition

Drugs approved for chronic constipation

Brand-name prescription drugs and biologics whose FDA label lists chronic constipation as an approved use. Matched on the label phrases: "chronic idiopathic constipation", "opioid-induced constipation".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

8

Still marketed, NDA or BLA

Drug classes

3

Novel drugs

7

New molecular entities and new biologics

In development

0

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for chronic constipation.

  • Motegrity (Prucalopride Succinate) · Takeda Pharms USA NovelDec 14, 2018
  • Symproic (Naldemedine Tosylate) · Bdsi NovelMar 23, 2017
  • Trulance (Plecanatide) · Salix NovelJan 19, 2017
  • Relistor (Methylnaltrexone Bromide) · Salix Jul 19, 2016
  • Movantik (Naloxegol Oxalate) · Averitas NovelSep 16, 2014

All approved drugs for chronic constipation, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 18 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Guanylate Cyclase-C Agonist (2)

Chloride Channel Activator (1)

  • Amitiza Lubiprostone · Sucampo Pharma LLC · 2006

Class not listed in FDA's data (5)

  • Motegrity Prucalopride Succinate · Takeda Pharms USA · 2018
  • Symproic Naldemedine Tosylate · Bdsi · 2017
  • Movantik Naloxegol Oxalate · Averitas · 2014
  • Relistor Methylnaltrexone Bromide · Salix Pharms · 2008
  • Relistor Methylnaltrexone Bromide · Salix · 2016

Drugs in development for chronic constipation

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline

No investigational drugs in Phase 2 or 3 trials list this condition.

More on chronic constipation: recruiting trials · published research

Related in gastroenterology and liver: MASH (fatty liver disease) · Primary biliary cholangitis · Acid reflux (GERD) · Irritable bowel syndrome · Nausea and vomiting · Eosinophilic esophagitis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.